Respiratory Syncytial Virus Infection: Treatments and Clinical Management

Shiza Malik, Tahir Ahmad, Khalid Muhammad, Yasir Waheed

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-compromised individuals and infants below 5 years of age. Worldwide, it is known to be associated with incidences of morbidity and mortality in infants. Despite the seriousness of the issue and continuous rigorous scientific efforts, no approved vaccine or available drug is fully effective against RSV. The purpose of this review article is to provide insights into the past and ongoing efforts for securing effective vaccines and therapeutics against RSV. The readers will be able to confer the mechanism of existing therapies and the loopholes that need to be overcome for future therapeutic development against RSV. A methodological approach was applied to collect the latest data and updated results regarding therapeutics and vaccine development against RSV. We outline the latest throughput vaccination technologies and prophylactic development efforts linked with RSV. A range of vaccination approaches with the already available vaccine (with limited use) and those undergoing trials are included. Moreover, important drug regimens used alone or in conjugation with adjuvants or vaccines are also briefly discussed. After reading this article, the audience will be able to understand the current standing of clinical management in the form of the vaccine, prophylactic, and therapeutic candidates against RSV. An understanding of the biological behavior acting as a reason behind the lack of effective therapeutics against RSV will also be developed. The literature indicates a need to overcome the limitations attached to RSV clinical management, drugs, and vaccine development that could be explained by dealing with the challenges of current study designs with continuous improvement and further work and approval on novel therapeutic applications.

Original languageEnglish
Article number491
JournalVaccines
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 2023

Keywords

  • RSV infection
  • antiviral agents
  • clinical management
  • novel therapeutic
  • respiratory syncytial virus
  • therapeutics
  • therapies
  • treatment
  • vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Respiratory Syncytial Virus Infection: Treatments and Clinical Management'. Together they form a unique fingerprint.

Cite this